Category: Clinical Trials

A newly launched Phase I clinical trial is exploring an innovative treatment combination for patients facing metastatic, unresectable, or locally advanced urothelial carcinoma—a challenging form of bladder-related cancer. The study, registered on ClinicalTrials.gov, is testing the safety and optimal dosing of belinostat when paired with durvalumab, a monoclonal antibody immunotherapy also known as MEDI4736.

Durvalumab works by helping the immune system recognize and attack cancer cells more effectively, blocking signals that tumors use to evade immune detection. Belinostat, meanwhile, is a histone deacetylase (HDAC) inhibitor—a class of compound that interferes with enzymes involved in cell growth and survival. By inhibiting these enzymes, researchers hope belinostat can make cancer cells more vulnerable to the immune response triggered by durvalumab, potentially creating a synergistic effect that neither drug could achieve alone.

This type of combination approach reflects a broader and encouraging trend in oncology research: pairing immunotherapies with agents that modify the tumor’s biological environment to boost treatment effectiveness. For patients with advanced urothelial cancer—a diagnosis that often comes with limited options—early-phase trials like this one represent an important step toward expanding the therapeutic toolkit available to oncologists.

While this is a Phase I trial primarily focused on determining safe dosing and understanding side effects, the scientific rationale behind the combination is grounded in a growing body of research suggesting that HDAC inhibitors can enhance the effectiveness of immune checkpoint therapies. If the combination proves safe and shows signs of benefit, it could pave the way for larger studies aimed at confirming efficacy and ultimately offering new hope to patients with few alternatives.

Trials like this one are a reminder of the continuous innovation happening in cancer treatment research, where scientists are constantly searching for new ways to combine existing therapies for greater impact. As this study progresses, it will contribute valuable data to the broader effort of improving outcomes for people living with advanced urothelial cancer.

This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance regarding treatment options.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

A new international clinical trial has begun recruiting participants to study ABBV-901, an investigational therapy being developed for the treatment of ovarian cancer. The study, registered on ClinicalTrials.gov, represents a meaningful step forward in the search for new treatment options for this challenging disease.

The trial is notably comprehensive in scope, featuring six distinct study parts designed to carefully evaluate ABBV-901 both as a standalone treatment and in combination with other anticancer therapies, including bevacizumab and carboplatin. This structured, phased approach allows researchers to methodically assess dosing, safety, and how the body processes the drug before moving into larger combination therapy phases. Approximately 285 participants are expected to enroll across roughly 45 sites worldwide, reflecting a substantial global effort to generate robust data.

What makes this trial particularly encouraging is its combination-therapy design. Rather than testing ABBV-901 in isolation, researchers are also exploring how it may work alongside already-established treatments like bevacizumab and carboplatin, which are familiar components of ovarian cancer care. This approach could potentially help identify synergistic treatment strategies that build on existing standards of care rather than starting from scratch.

Ovarian cancer remains a serious health challenge, and the launch of new investigational studies like this one reflects the ongoing commitment within the research community to develop better tools for patients and clinicians. Trials of this nature—spanning dose escalation, optimization, and expansion phases—are foundational to bringing potential new therapies through the rigorous evaluation process required before they can become part of standard care.

While the study will require meaningful participation from volunteers, including regular visits, blood tests, and imaging, such thorough monitoring is a hallmark of responsible clinical research aimed at protecting participant safety while generating the data needed to understand a new therapy’s potential. The three-year study duration will allow researchers time to gather meaningful insights into both safety and efficacy outcomes.

This is an early-stage investigational trial, and it will be some time before results are available. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

A newly launched clinical trial is set to examine whether oral vancomycin, a well-known glycopeptide antibiotic, could offer a new treatment option for people living with both ulcerative colitis (UC) and primary sclerosing cholangitis (PSC), a rare liver condition that frequently accompanies inflammatory bowel disease. The study, registered on ClinicalTrials.gov, represents an encouraging step toward better understanding how targeted antibiotic therapy might help this specific and often under-studied patient population.

The trial will enroll adult participants who have active UC alongside PSC, randomly assigning them to receive either oral vancomycin (250 mg twice daily) or a matching placebo for four weeks. Those who complete the initial phase will have the option to continue with an additional four weeks of open-label vancomycin, allowing researchers to gather more insight into longer-term tolerability. Throughout the study, participants will undergo regular clinic visits that include Mayo score assessments, endoscopy, and blood and stool testing to monitor both UC activity and liver health.

What makes this study particularly promising is its thoughtful, feasibility-focused design. Rather than jumping straight to large-scale efficacy claims, the researchers are first asking foundational questions: Can enough participants be recruited and retained? Will adherence to the treatment protocol be strong? These are essential building blocks for any future, larger trial, and a well-run pilot study like this one helps ensure that subsequent research is built on a solid foundation.

Beyond feasibility, the trial will also collect valuable secondary data on safety, early signs of improvement in UC symptoms, liver function markers, and shifts in gut bacterial balance. Since PSC and UC often occur together and can be challenging to manage simultaneously, any research that explores treatments addressing both conditions is a welcome development. Oral vancomycin is already used in clinical settings for certain gastrointestinal infections, so examining its potential role in this dual-diagnosis population builds on existing, familiar ground rather than starting from scratch.

While results are still to come, the initiation of this trial reflects the kind of methodical, patient-centered research that can eventually lead to improved treatment pathways for people managing these intertwined conditions. True North Labs will continue to follow this study as it progresses and share updates on what researchers learn.

This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance on any treatment or clinical trial participation.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis

Exciting news is unfolding in the world of peptide-based therapeutics: a new Phase 3 clinical trial, known as SUNRISE 2, has been launched to study oral VK2735 for weight management in adults living with Type 2 Diabetes Mellitus. This trial specifically targets individuals who are classified as overweight (BMI ≥ 27 kg/m2) or obese (BMI ≥ 30 kg/m2), representing a significant population that often faces complex challenges in managing both blood sugar and body weight simultaneously.

SUNRISE 2 is one of two planned Phase 3 studies designed to support a potential weight management indication for oral VK2735. The advancement to Phase 3 status is a meaningful milestone in drug development, as it typically follows encouraging results from earlier-phase studies and signals that researchers and regulators see strong enough promise to warrant larger, more definitive trials involving broader patient groups.

What makes this development particularly noteworthy is the oral formulation of VK2735. Many current peptide-based weight management and metabolic therapies require injection, so an effective oral option could offer a more convenient and accessible alternative for patients. For individuals managing Type 2 Diabetes alongside weight concerns, having additional treatment formats to discuss with their healthcare providers may help support more personalized and sustainable approaches to care.

The focus on this dual population—those with both elevated body weight and Type 2 Diabetes—reflects a growing recognition in the medical community of how interconnected these health factors can be. Trials like SUNRISE 2 contribute valuable data that may eventually help inform treatment guidelines and expand the toolkit available to clinicians and patients alike. As this study progresses, it adds to the broader momentum within peptide research aimed at addressing metabolic health challenges.

We’ll continue to follow the progress of SUNRISE 2 and related studies as they move through the clinical trial process. This article is for informational purposes only and is not intended as medical advice; individuals should consult their healthcare provider for guidance specific to their health needs.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

People living with HIV, even those whose infection is well-controlled with modern antiretroviral therapy, face a higher risk of cardiovascular disease compared to the general population. A newly registered clinical trial, known as the ENCHANTMENT HIV Study, is taking aim at this challenge by examining the role of two important hormones: aldosterone and brain natriuretic peptide (BNP).

Both aldosterone and BNP play key roles in regulating blood pressure, fluid balance, and heart function. Prior research has shown that these hormones can become dysregulated in people with HIV, potentially contributing to inflammation and early structural changes in the heart. By studying therapies designed to block aldosterone activity while supporting healthy BNP levels, researchers hope to better understand how these hormonal pathways influence cardiovascular health in this population.

The goal of the ENCHANTMENT HIV Study is to determine whether this combined hormonal approach can help reduce the burden of heart-related complications and potentially slow the progression toward heart failure. This represents a proactive and targeted strategy, moving beyond general cardiovascular risk management to address specific biological mechanisms that may be unique to people living with HIV.

What makes this research especially encouraging is its focus on prevention and early intervention. Rather than waiting for cardiovascular disease to become advanced, the study is designed to catch and address subtle changes in heart structure and function before they progress. If successful, this approach could pave the way for new, more personalized cardiovascular care strategies tailored to the needs of people living with HIV.

As the trial progresses, it adds to a growing body of research exploring how peptide hormones like BNP can be leveraged not just as diagnostic markers, but as potential therapeutic targets. Studies like this highlight the ongoing commitment within the medical research community to improve long-term health outcomes for people with HIV, extending the focus of care beyond viral suppression to overall well-being and longevity.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: The ENCHANTMENT HIV Study

A newly launched clinical trial is investigating a promising approach to safeguarding heart health in patients undergoing radiation therapy for non-small cell lung cancer. Researchers will track two blood-based biomarkers, Pro-N-Cadherin and NT-proBNP, a well-studied peptide hormone linked to heart function, to see whether early changes in these markers can signal a patient’s risk of developing radiation-related heart problems.

Hypofractionated radiation therapy, a treatment that delivers higher doses over fewer sessions, has become an important option for many lung cancer patients because it can be more convenient and efficient. However, because the heart sits close to the lungs, radiation exposure to cardiac tissue is an ongoing concern for oncologists. This trial aims to give doctors a clearer, more proactive way to monitor that risk in real time.

Over a two-year follow-up period, participants will undergo routine blood collection and echocardiography, allowing researchers to compare biomarker levels against actual radiation dose to the heart and any resulting cardiac dysfunction or adverse events. The ultimate goal is to determine whether simple blood tests could one day help clinicians identify at-risk patients earlier, potentially allowing for adjusted treatment plans or closer cardiac monitoring before serious complications develop.

What makes this research particularly encouraging is its focus on prevention and personalization. If Pro-N-Cadherin and NT-proBNP prove to be reliable early indicators, oncologists could gain a valuable, minimally invasive tool to tailor radiation therapy more safely for individual patients. This kind of biomarker-driven approach reflects a broader, positive trend in cancer care: using precise, measurable biological signals to reduce treatment side effects while preserving the effectiveness of life-saving therapies.

As the trial progresses, its findings could contribute meaningfully to safer cancer treatment protocols and improved quality of life for patients navigating both cancer and cardiovascular health. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer Patients

A new comparative-effectiveness clinical trial, known as DECIDE, is underway to help expand treatment options for individuals diagnosed with gestational diabetes mellitus (GDM). The study will enroll 1,572 pregnant participants across 20 sites in the United States, comparing the effectiveness and safety of oral metformin against injectable insulin—the current standard treatment—for managing blood sugar levels during pregnancy.

Insulin, a naturally occurring peptide hormone, has long been the primary pharmacological treatment for GDM when lifestyle changes alone aren’t enough to manage blood sugar. However, insulin requires injections, which can be a barrier for some patients. Metformin, an oral medication, has grown in use as an alternative, but more robust, large-scale evidence is needed to confirm whether it performs comparably to insulin in protecting both parent and child health outcomes.

What makes this trial especially encouraging is its patient-centered design. Beyond measuring clinical outcomes like pregnancy complications, researchers will also track patient-reported experiences—identifying what makes a treatment easier or harder to follow. This kind of real-world insight can help clinicians tailor care recommendations based on what actually works best for patients’ daily lives, not just lab results.

The study’s extended follow-up period, tracking both parents and children for two years postpartum, is also a notable strength. This long-term view will help build a fuller picture of safety and developmental outcomes, giving future parents and their doctors more confidence when making treatment decisions. If metformin proves to be non-inferior to insulin, it could offer a more convenient, non-injectable option for many pregnant individuals managing GDM—potentially easing treatment burden without compromising safety.

Trials like DECIDE reflect the ongoing effort to refine and personalize care for pregnancy-related conditions, ensuring that both established peptide-based treatments like insulin and emerging oral alternatives are rigorously evaluated. As more comparative data becomes available, patients and providers alike stand to benefit from clearer, evidence-based guidance. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

A new clinical trial is examining how several positron emission tomography (PET) tracers, including the widely used [18F]FDG, might help clinicians better visualize active granulomas in patients with pulmonary sarcoidosis. Sarcoidosis is an inflammatory condition that can cause small clusters of immune cells, known as granulomas, to form in the lungs, and accurately identifying active disease has traditionally been a challenge for physicians.

The study is evaluating tracers that are already approved and in routine clinical use for detecting other types of inflammation or certain tumors. Because the molecular pathways involved in these conditions share some similarities with the processes seen in sarcoidosis, researchers are hopeful that these existing imaging agents could be repurposed to offer a clearer picture of disease activity in the lungs.

One of the promising aspects of this approach is that it builds on tracers with established safety profiles, rather than requiring entirely new compounds to go through the full development pipeline. If successful, this could mean a faster path toward improved diagnostic tools, giving doctors more precise ways to track how active a patient’s sarcoidosis is over time and potentially guide treatment decisions with greater confidence.

Better imaging techniques could also reduce reliance on more invasive diagnostic procedures, offering patients a more comfortable path to accurate assessment. As the trial progresses, researchers will be looking at how well each tracer highlights areas of active inflammation, which could eventually help clinicians distinguish between active and inactive disease stages more reliably.

This kind of research reflects the broader value of exploring new applications for existing medical tools, potentially accelerating the timeline for bringing improved diagnostic options to patients living with pulmonary sarcoidosis. As always, this article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis

Researchers have launched a phase II clinical trial examining a promising combination approach for small cell lung cancer and other high-grade neuroendocrine carcinomas—cancers that are notoriously difficult to treat and in need of new therapeutic options. The study pairs niraparib, a PARP inhibitor, with dostarlimab, a monoclonal antibody immunotherapy, to see whether combining these two distinct treatment strategies can offer better outcomes for patients.

Niraparib works by blocking PARP, an enzyme that cancer cells rely on to repair damaged DNA. By inhibiting this repair process, the therapy aims to make it harder for cancer cells to survive, potentially causing them to die off more effectively. This targeted approach has already shown value in other cancer types, and researchers are now exploring its potential in the challenging landscape of neuroendocrine carcinomas.

Dostarlimab, meanwhile, is designed to help the immune system recognize and attack cancer cells more effectively. As a monoclonal antibody therapy, it may also interfere with tumor cells’ ability to grow and spread, offering a complementary mechanism to the DNA-repair-blocking action of niraparib. The hope is that using these two approaches together could provide a more powerful one-two punch than either treatment alone.

What makes this trial particularly encouraging is its focus on a group of cancers—small cell lung cancer and high-grade neuroendocrine carcinomas—that have historically had limited treatment options and challenging prognoses. Phase II trials like this one are a critical step in the research pipeline, helping scientists understand whether a combination therapy is both safe and effective enough to warrant larger-scale studies. Progress in this area could eventually translate into more choices and better outcomes for patients facing these difficult diagnoses.

As with all clinical research, it will take time to gather and analyze results, but the initiation of this trial reflects the ongoing commitment of the oncology research community to innovate and improve care for patients with aggressive, hard-to-treat cancers. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas